Argatroban (MCI-9038) - Moligand™, 10mM in DMSO , Thrombin inhibitor, CAS No.74863-84-6, Thrombin inhibitor

CAS: 74863-84-6 Cat. No.: A408293 Peso molecular: 508.63 Número EC: 638-764-8

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

(2R,​4R)​-1-​[(2S)​-​5-​[(aminoiminomethyl)​amino]​-​1-​oxo-​2-​[[(1,​2,​3,​4-​tetrahydro-​3-​methyl-​8-​quinolinyl)​sulfonyl]​amino]​pentyl]​-​4-​methyl-2-​piperidinecarboxylic acid

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Descripción general

Information

Argatroban (MCI-9038) Argatroban (MCI-9038) is a potent and selective synthetic thrombin inhibitor with K i ranging from 5 nM to 39 nM, used as an anticoagulant.
In vitro

Argatroban is a potent and selective synthetic thrombin inhibitor with Ki values against thrombin ranging from 5 nM to 39 nM. Argatroban has antithrombotic properties in a wide variety of animal models of both platelet-rich and erythrocyte-rich thrombosis. Argatroban dose-dependently prevents thrombus formation with an estimated ED50 of 125 μg/kg in this test. Argatroban produces a dose-dependent increases in the thrombin time with a 511% increase at the highest dose used with only a 73% increase in the APTT at this dose. Argatroban can directly induce phenotype conversion of vascular smooth muscle cells with the resultant up-regulation of SMemb, PAI-1, and beta-actin mRNAs.

In vivo

Argatroban inhibits the formation of microthrombi up to 3 hours after middle cerebral artery (MCA) occlusion; beyond 3 hours, it is ineffective. Argatroban also significantly reduces the size of ischemic cerebral lesions at 6 hours after MCA occlusion. Argatroban (0.3 mg/h/rat) significantly decreases the number of microthrombi 1 day after distal middle cerebral artery (dMCA) occlusion in the rat distal middle cerebral artery occlusion model. Argatroban (0.1 and 0.3 mg/h/rat) significantly reverses a decrease in regional cerebral blood flow (rCBF) 1 day after distal middle cerebral artery (dMCA) occlusion. Argatroban (0.3 mg/h/rat) also significantly reduces the size of the cerebral infarction.
Cell Data

cell lines：Normal human dermal fibroblasts, Scleroderma fibroblasts

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Sinónimos

(2R, ​4R)​-1-​[(2S)​-​5-​[(aminoiminomethyl)​amino]​-​1-​oxo-​2-​[[(1, ​2, ​3, ​4-​tetrahydro-​3-​methyl-​8-​quinolinyl)​sulfonyl]​amino]​pentyl]​-​4-​methyl-2-​piperidinecarboxylic acid

Especificaciones y pureza

Moligand™, 10mM in DMSO

Mecanismos bioquímicos y fisiológicos

Argatroban (MCI-9038) is a potent and selective synthetic thrombin inhibitor with K_i ranging from 5 nM to 39 nM, used as an anticoagulant.

Condiciones de almacenamiento de almacenamiento

Store at -80°C

Enviado en

Dry ice packs + Cold packs

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Grado

Moligand™

Tipo de acción

INHIBITOR

Mecanismo de acción

Thrombin inhibitor

Propiedades del producto

• ALogP: 1.3

Nombres e identificadores

• Isómeros SMILES: C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C
• Peso molecular: 508.63
• Reaxy-Rn: 24866985
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=24866985&ln=

Objetivos asociados (humanos)

F2 Tclin Prothrombin (24 Activities)

Discover Target: F2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Propiedades químicas y físicas

• Solubilidad: Solubility (25°C) In vitro DMSO: 100 mg/mL (127.38 mM); Ethanol: 100 mg/mL (127.38 mM); Water: 10 mg/mL (12.73 mM)
• Punto de fusión (°C): 180°C

Referencias

1. Ru Li, Xuan Zou, Pan Luan, Xiaokun Liu, Ning Wang, Qian Wang, Huashi Guan, Zhe Xu.  (2022)  Direct Determination of Enzymes in Dried Blood Spots by High-Performance Liquid Chromatography – Mass Spectrometry (HPLC-MS) for the Screening of Antithrombotic Agents.  ANALYTICAL LETTERS,      [PMID:] [10.1080/00032719.2022.2053700]

2. Zhe Xu, Ruonan Liu, Huashi Guan.  (2017)  Dual-target inhibitor screening against thrombin and factor Xa simultaneously by mass spectrometry.  ANALYTICA CHIMICA ACTA,      [PMID:29029731] [10.1016/j.aca.2017.07.063]

3. Xiaoxuan Fan, Shuxian Zhang, Keshuai Liu, Xiaofei Wang, Hui Yuan, Zhiping Lv, Lijuan Ma, Xueqin Ma, Xia Zhang, Guoning Chen.  (2024)  Integration of paper-based colorimetric microdevice and magnetic nanoparticles affinity for high-throughput capture of antimicrobial resistance-reversing agent from complex natural products.  BIOSENSORS & BIOELECTRONICS,      [PMID:39752886] [10.1016/j.bios.2024.117107]

4. Shuxian Zhang, Xiaofei Wang, Jili Han, Xiaoxuan Fan, Keshuai Liu, Lingling Yang, Hao Yang, Xiaofei Chen, Xueqin Ma, Guoning Chen.  (2025)  Precise Identification of Inhibitors for Coagulation Reactions from Complex Extracts through Monitoring of Biological Aggregates Combined with a Targeted Fishing Technique.  ANALYTICAL CHEMISTRY,      [PMID:40073066] [10.1021/acs.analchem.4c07092]

5. Lv Keyu, Chen Shuai, Xu Xulin, Chiu Joyce, Wang Haoqing J., Han Yunyun, Yang Xiaodan, Bowley Sheryl R., Wang Hao, Tang Zhaoming, Tang Ning, Yang Aizhen, Yang Shuofei, Wang Jinyu, Jin Si, Wu Yi, Schmaier Alvin H., Ju Lining A., Hogg Philip J., Fang Chao.  (2024)  Protein disulfide isomerase cleaves allosteric disulfides in histidine-rich glycoprotein to regulate thrombosis.  Nature Communications,  15  (1): (1-19).  [PMID:38605050] [10.1038/s41467-024-47493-0]

6. Qian Qin, Jinwei Zhang, Guo Feng, Yinhao Liao, Youli Chen, Caiyao Han, Yan Lei, Kexin Ma, Wei Li, Yibao Jin, Jinxi Wang, Ping Wang, Bing Wang, Xie-an Yu.  (2026)  Exploring the changes in anticoagulant active ingredients before and after bovine bile fermentation of the traditional Chinese medicine Yaomu via an aggregation-induced emission fluorescence sensor.  RSC Advances,  16  (6): (5220-5227).  [PMID:41584138] [10.1039/d5ra09117a]

7. Lingling Yang, Shuxian Zhang, Xiaoxuan Fan, Keshuai Liu, Rui Mai, Wangyan Zhao, Qiang Han, Yongjian Ai, Qionglin Liang, Xueqin Ma, Guoning Chen.  (2026)  Rapid and Sensitive Screening of Carbonic Anhydrase Natural Inhibitors in Traditional Chinese Medicine via a Carbon Quantum Dot-Affinity Adsorption Nanosystem.  Journal of Pharmaceutical Analysis,      [PMID:] [10.1016/j.jpha.2026.101607]